Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
J Clin Endocrinol Metab (2005) 90:106871.10.1210/jc.2004-1216 26 ShiiyaTNakazatoMMizutaMDateYMondalMSTanakaMet alPlasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion
Xu L, Yu H, Sun H, Hu B, Geng Y
Clinicians should: Assess baseline HbA1c and current glycemic control before discontinuation Implement or intensify alternative therapies (metformin, SGLT2 inhibitors, or other agents) before or concurrent with tirzepatide cessation Increase home glucose monitoring frequency for several weeks post-discontinuation Schedule follow-up to evaluate metabolic stability Special consideration for insulin or sulfonylurea users : Patients taking these medications alongside tirzepatide may need proactive dose adjustments when stopping tirzepatide to prevent hypoglycemia
In the largest Wegovy study, the participants given Wegovy shed an average of 15 percent of their total body weight over a period of 68 weeks or almost 16 months
Patients and physicians are both learning of various benefits and off-label indications for this group of medications, referred to as glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
